Impairing the PKC-θ activity is believed to be a promising therapeutic strategy against the undesired immune response, such as Th2-mediated allergies, Th17-associated autoimmune diseases (63), and GvHD (49), meanwhile preserving the beneficial Th1 and CTL anti-pathogen immunity (47, 81) as well as GvL response in BMT (49). Here, PRRT2 is linked to autoimmune disease.